Ligand Pharmaceuticals Incorporated (LGND)
USD 109.39
(0.22%)
USD 109.39
(0.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 101.72 Million USD | 486.48% |
| 2022 | 54.4 Million USD | -92.55% |
| 2021 | 133.16 Million USD | 266.35% |
| 2020 | 69.05 Million USD | 103.98% |
| 2019 | 38.01 Million USD | -548.17% |
| 2018 | 238.29 Million USD | 116.87% |
| 2017 | 81.15 Million USD | 38.13% |
| 2016 | 55.17 Million USD | 867.8% |
| 2015 | 29.95 Million USD | -77.01% |
| 2014 | 23.36 Million USD | 30.6% |
| 2013 | 18.64 Million USD | 622.49% |
| 2012 | 3.94 Million USD | 261.24% |
| 2011 | 1.74 Million USD | 95.3% |
| 2010 | -13.13 Million USD | -21.49% |
| 2009 | -6.46 Million USD | -164.63% |
| 2008 | -96.26 Million USD | 182.32% |
| 2007 | -50.1 Million USD | 62.85% |
| 2006 | -61.86 Million USD | -726.77% |
| 2005 | -26.47 Million USD | 49.54% |
| 2004 | -18.26 Million USD | -3252.09% |
| 2003 | -59.68 Million USD | 111.43% |
| 2002 | -35.13 Million USD | -27.34% |
| 2001 | -16.56 Million USD | 78.47% |
| 2000 | -38.63 Million USD | 11.84% |
| 1999 | -54.19 Million USD | -128.57% |
| 1998 | -65.1 Million USD | -146.9% |
| 1997 | -21 Million USD | 248.16% |
| 1996 | -23.5 Million USD | -315.87% |
| 1995 | -21.2 Million USD | 197.67% |
| 1994 | -18.4 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 16.74 Million USD | -547.76% |
| 2024 Q1 | 12.23 Million USD | -54.12% |
| 2023 Q1 | -16.78 Million USD | 69.92% |
| 2023 Q2 | 2.56 Million USD | 115.28% |
| 2023 FY | - USD | 486.48% |
| 2023 Q4 | 9.87 Million USD | -57.91% |
| 2023 Q3 | 23.45 Million USD | 814.54% |
| 2022 Q4 | -55.8 Million USD | -517.19% |
| 2022 Q1 | 5.2 Million USD | -75.41% |
| 2022 FY | - USD | -92.55% |
| 2022 Q3 | 13.37 Million USD | 0.85% |
| 2022 Q2 | 13.26 Million USD | 154.83% |
| 2021 Q2 | 64.38 Million USD | 1771.57% |
| 2021 Q4 | 21.16 Million USD | -30.32% |
| 2021 FY | - USD | 266.35% |
| 2021 Q1 | 3.44 Million USD | 131.07% |
| 2021 Q3 | 30.37 Million USD | -52.82% |
| 2020 FY | - USD | 103.98% |
| 2020 Q1 | 7.32 Million USD | 159.27% |
| 2020 Q2 | 12.77 Million USD | 74.49% |
| 2020 Q3 | 7.4 Million USD | -42.06% |
| 2020 Q4 | -11.07 Million USD | -249.55% |
| 2019 FY | - USD | -548.17% |
| 2019 Q1 | -795.54 Million USD | -2271.73% |
| 2019 Q2 | -625 Thousand USD | 99.92% |
| 2019 Q3 | -1.6 Million USD | -156.96% |
| 2019 Q4 | -12.35 Million USD | -669.3% |
| 2018 Q3 | 96.15 Million USD | -14.41% |
| 2018 Q2 | 112.33 Million USD | 172.14% |
| 2018 Q1 | 41.27 Million USD | 26.54% |
| 2018 Q4 | 36.63 Million USD | -61.9% |
| 2018 FY | - USD | 116.87% |
| 2017 Q2 | 16.54 Million USD | 24.08% |
| 2017 Q3 | 20.53 Million USD | 24.11% |
| 2017 FY | - USD | 38.13% |
| 2017 Q1 | 13.33 Million USD | -42.43% |
| 2017 Q4 | 32.62 Million USD | 58.86% |
| 2016 Q3 | 9.21 Million USD | 11.42% |
| 2016 FY | - USD | 867.8% |
| 2016 Q4 | 23.16 Million USD | 151.41% |
| 2016 Q2 | 8.26 Million USD | -57.41% |
| 2016 Q1 | 19.41 Million USD | 68.54% |
| 2015 Q2 | -16.11 Million USD | -462.3% |
| 2015 Q3 | 7.63 Million USD | 147.35% |
| 2015 FY | - USD | -77.01% |
| 2015 Q4 | 11.51 Million USD | 50.97% |
| 2015 Q1 | 4.44 Million USD | -59.62% |
| 2014 FY | - USD | 30.6% |
| 2014 Q3 | 5.51 Million USD | 87.49% |
| 2014 Q1 | 8.12 Million USD | -24.72% |
| 2014 Q4 | 11.01 Million USD | 99.71% |
| 2014 Q2 | 2.94 Million USD | -63.79% |
| 2013 FY | - USD | 622.49% |
| 2013 Q3 | 4.05 Million USD | 727.76% |
| 2013 Q4 | 10.79 Million USD | 166.07% |
| 2013 Q2 | 490 Thousand USD | -92.6% |
| 2013 Q1 | 6.62 Million USD | -12.25% |
| 2012 Q2 | 268 Thousand USD | 123.04% |
| 2012 FY | - USD | 261.24% |
| 2012 Q1 | -1.16 Million USD | -118.18% |
| 2012 Q4 | 7.54 Million USD | 367.36% |
| 2012 Q3 | -2.82 Million USD | -1152.99% |
| 2011 Q4 | 6.39 Million USD | 1847.81% |
| 2011 Q1 | -2.19 Million USD | 28.3% |
| 2011 Q2 | -467 Thousand USD | 78.71% |
| 2011 FY | - USD | 95.3% |
| 2011 Q3 | -366 Thousand USD | 21.63% |
| 2010 Q1 | -3.49 Million USD | -348.9% |
| 2010 FY | - USD | -21.49% |
| 2010 Q4 | -3.06 Million USD | 79.53% |
| 2010 Q2 | -2.8 Million USD | 19.73% |
| 2010 Q3 | -14.94 Million USD | -432.49% |
| 2009 Q3 | -19.95 Million USD | -348.64% |
| 2009 Q4 | 1.4 Million USD | 107.04% |
| 2009 Q2 | -4.44 Million USD | 28.25% |
| 2009 Q1 | -6.19 Million USD | -108.71% |
| 2009 FY | - USD | -164.63% |
| 2008 Q3 | -5.44 Million USD | -2.04% |
| 2008 FY | - USD | 182.32% |
| 2008 Q1 | -11.9 Million USD | -74.94% |
| 2008 Q4 | 71.12 Million USD | 1406.8% |
| 2008 Q2 | -5.33 Million USD | 55.21% |
| 2007 FY | - USD | 62.85% |
| 2007 Q3 | -8.91 Million USD | 36.0% |
| 2007 Q2 | -13.93 Million USD | 50.57% |
| 2007 Q1 | -28.18 Million USD | 79.69% |
| 2007 Q4 | -6.8 Million USD | 23.65% |
| 2006 Q4 | -138.78 Million USD | -1796.16% |
| 2006 FY | - USD | -726.77% |
| 2006 Q3 | -7.31 Million USD | 14.2% |
| 2006 Q1 | -135.72 Million USD | -11216.22% |
| 2006 Q2 | -8.53 Million USD | 93.72% |
| 2005 Q2 | -6.07 Million USD | 54.13% |
| 2005 FY | - USD | 49.54% |
| 2005 Q3 | -880 Thousand USD | 85.52% |
| 2005 Q4 | 1.22 Million USD | 238.75% |
| 2005 Q1 | -13.25 Million USD | 45.42% |
| 2004 Q4 | -24.28 Million USD | -10891.56% |
| 2004 Q3 | 225 Thousand USD | 102.96% |
| 2004 Q2 | -7.59 Million USD | -17.93% |
| 2004 Q1 | -6.44 Million USD | -144.85% |
| 2004 FY | - USD | -3252.09% |
| 2003 Q4 | 14.23 Million USD | 426.45% |
| 2003 Q1 | -8.93 Million USD | 14.04% |
| 2003 FY | - USD | 111.43% |
| 2003 Q2 | -5.53 Million USD | -42.37% |
| 2003 Q3 | -4.66 Million USD | 14.58% |
| 2002 Q2 | -7.75 Million USD | -581.02% |
| 2002 Q4 | -4.2 Million USD | 11.46% |
| 2002 FY | - USD | -27.34% |
| 2002 Q1 | -723 Thousand USD | -75.87% |
| 2002 Q3 | -5.01 Million USD | 35.99% |
| 2001 Q1 | -6.66 Million USD | 63.1% |
| 2001 Q4 | -1.21 Million USD | 341.16% |
| 2001 Q3 | -2.84 Million USD | 54.08% |
| 2001 FY | - USD | 78.47% |
| 2001 Q2 | -5.83 Million USD | 6.32% |
| 2000 Q2 | -9.55 Million USD | -93.63% |
| 2000 Q4 | -15.25 Million USD | -124.75% |
| 2000 Q3 | -10.43 Million USD | 19.03% |
| 2000 FY | - USD | 11.84% |
| 2000 Q1 | -7.13 Million USD | 49.53% |
| 1999 Q2 | -13.4 Million USD | -39.58% |
| 1999 Q3 | -11.03 Million USD | 19.4% |
| 1999 FY | - USD | -128.57% |
| 1999 Q1 | -9.6 Million USD | -45.45% |
| 1999 Q4 | -14.9 Million USD | 12.96% |
| 1998 Q1 | -10.8 Million USD | -116.64% |
| 1998 FY | - USD | -146.9% |
| 1998 Q4 | -21.6 Million USD | -151.16% |
| 1998 Q3 | -15.1 Million USD | 189.58% |
| 1998 Q2 | -14.4 Million USD | -33.33% |
| 1997 Q3 | -7.8 Million USD | -7.5% |
| 1997 Q4 | 800 Thousand USD | 854.65% |
| 1997 FY | - USD | 248.16% |
| 1997 Q1 | -6.8 Million USD | 11.24% |
| 1997 Q2 | -7.1 Million USD | -1.27% |
| 1996 FY | - USD | -315.87% |
| 1996 Q1 | -5 Million USD | 17.57% |
| 1996 Q2 | -7.7 Million USD | -40.98% |
| 1996 Q3 | -2.4 Million USD | 63.95% |
| 1996 Q4 | -8.1 Million USD | -187.1% |
| 1995 FY | - USD | 197.67% |
| 1995 Q1 | -3.4 Million USD | -5.0% |
| 1995 Q4 | -6.2 Million USD | 7.5% |
| 1995 Q3 | -6.8 Million USD | -248.15% |
| 1995 Q2 | 5.4 Million USD | 357.14% |
| 1994 Q2 | -5.4 Million USD | -2.56% |
| 1994 FY | - USD | 0.0% |
| 1994 Q3 | -4.4 Million USD | 22.5% |
| 1994 Q4 | -3.4 Million USD | 35.48% |
| 1994 Q1 | -5.2 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Absci Corporation | -95.45 Million USD | 206.568% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 153.746% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 139.392% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 1128.906% |
| Apollomics, Inc. | -171.74 Million USD | 159.231% |
| 180 Life Sciences Corp. | -22.13 Million USD | 559.596% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 424.447% |
| Bicycle Therapeutics plc | -183.4 Million USD | 155.467% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 235.972% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 161.496% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 572.292% |
| Chimerix, Inc. | -92.97 Million USD | 209.414% |
| CRISPR Therapeutics AG | -202.7 Million USD | 150.186% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -331.54% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 247.428% |
| Fortress Biotech, Inc. | -133.64 Million USD | 176.118% |
| Fortress Biotech, Inc. | -133.64 Million USD | 176.118% |
| Gritstone bio, Inc. | -126.86 Million USD | 180.187% |
| Allakos Inc. | -189.91 Million USD | 153.564% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 309.846% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 186.466% |
| Cytokinetics, Incorporated | -456.68 Million USD | 122.275% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 207.339% |
| Innoviva, Inc. | 248.96 Million USD | 59.139% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 66523.548% |
| NLS Pharmaceutics AG | -11.79 Million USD | 962.411% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 180.835% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 789606.158% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 199.473% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 214.989% |
| ImmuCell Corporation | -2.5 Million USD | 4162.455% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 177.999% |
| Incyte Corporation | 919.42 Million USD | 88.936% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 178.017% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 1692.314% |
| Mustang Bio, Inc. | -48.06 Million USD | 311.653% |
| MiMedx Group, Inc. | 40.51 Million USD | -151.072% |
| MEI Pharma, Inc. | 26.38 Million USD | -285.622% |
| MacroGenics, Inc. | 2.01 Million USD | -4943.48% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -23610.432% |
| Mereo BioPharma Group plc | -26.05 Million USD | 490.417% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 962.658% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 181.059% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 85.721% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 568.973% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 740.598% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 1056.71% |
| NextCure, Inc. | -59.03 Million USD | 272.305% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 298.612% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 1120.536% |
| Onconetix, Inc. | -36.7 Million USD | 377.135% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -4451.544% |
| Opthea Limited | -200.01 Million USD | 150.859% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 273.261% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 3797.04% |
| PDS Biotechnology Corporation | -40.08 Million USD | 353.778% |
| Precigen, Inc. | -89.22 Million USD | 214.01% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 546.916% |
| Prime Medicine, Inc. | -193.75 Million USD | 152.502% |
| PureTech Health plc | -11.62 Million USD | 974.92% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 142.991% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 97.814% |
| Replimune Group, Inc. | -230.19 Million USD | 144.191% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 106947.114% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 699.064% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 665.985% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 123.625% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 521.895% |
| Sesen Bio, Inc. | -50.84 Million USD | 300.092% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 216.357% |
| Solid Biosciences Inc. | -93.43 Million USD | 208.876% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 144.24% |
| SciSparc Ltd. | -5.28 Million USD | 2025.918% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 249.786% |
| TG Therapeutics, Inc. | 26.1 Million USD | -289.759% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 189.165% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 1519.777% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 131.181% |
| UroGen Pharma Ltd. | -63.83 Million USD | 259.369% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 263.556% |
| XOMA Corporation | -39.36 Million USD | 358.44% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 136.924% |
| AbCellera Biologics Inc. | -192.15 Million USD | 152.939% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 279.242% |
| Cassava Sciences, Inc. | -95.68 Million USD | 206.312% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 328.926% |
| Precision BioSciences, Inc. | -32.04 Million USD | 417.48% |
| Dyadic International, Inc. | -8.22 Million USD | 1336.09% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 1108.596% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 35057.732% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 447.69% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 183.038% |
| IGM Biosciences, Inc. | -253.35 Million USD | 140.151% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 194.981% |
| Acelyrin, Inc. | -381.52 Million USD | 126.663% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 301.153% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 610.873% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 520.951% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 164.714% |
| Senti Biosciences, Inc. | -61.33 Million USD | 265.852% |
| Mesoblast Limited | -61.33 Million USD | 265.866% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 171.038% |
| ChromaDex Corporation | -3.89 Million USD | 2712.404% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 2223.087% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 1581.174% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -41049.036% |
| Seer, Inc. | -97.88 Million USD | 203.925% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 528.595% |
| Novavax, Inc. | -487.39 Million USD | 120.872% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 4621.765% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 159.065% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 295.074% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 145.162% |
| Celcuity Inc. | -58.3 Million USD | 274.459% |
| ContextLogic Inc. | -324 Million USD | 131.397% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 163.96% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 231.527% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 92.982% |
| Amarin Corporation plc | -50.9 Million USD | 299.851% |
| AnaptysBio, Inc. | -143.16 Million USD | 171.056% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 459.32% |
| Aptorum Group Limited | -9.59 Million USD | 1159.767% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 143.276% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 157.907% |
| Ardelyx, Inc. | -55.35 Million USD | 283.775% |
| Celularity Inc. | -183.94 Million USD | 155.303% |
| Omeros Corporation | -163.61 Million USD | 162.177% |
| Humacyte, Inc. | -96.45 Million USD | 205.462% |
| Immunocore Holdings plc | -59.64 Million USD | 270.543% |
| IO Biotech, Inc. | -91.22 Million USD | 211.509% |
| GT Biopharma, Inc. | 5.97 Million USD | -1601.405% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 238.907% |
| Summit Therapeutics Inc. | 1 Million USD | -10062.537% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 429.171% |
| Pulmatrix, Inc. | -12.64 Million USD | 904.42% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 120.092% |
| Evogene Ltd. | -23.2 Million USD | 538.403% |
| CorMedix Inc. | -48.88 Million USD | 308.086% |
| BioLineRx Ltd. | -57.06 Million USD | 278.278% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 413.459% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 430.927% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 130.795% |
| scPharmaceuticals Inc. | -46.06 Million USD | 320.853% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 193.765% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 6.09% |
| NLS Pharmaceutics AG | -11.79 Million USD | 962.411% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 521.895% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 168.443% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 845.089% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 498.632% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 190.582% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 223.706% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 277.299% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 671.189% |
| Daré Bioscience, Inc. | -30.7 Million USD | 431.342% |
| bluebird bio, Inc. | -167.16 Million USD | 160.856% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 67.215% |
| DBV Technologies S.A. | -85.98 Million USD | 218.312% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 143.567% |
| Galecto, Inc. | -37.51 Million USD | 371.135% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 404.7% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 314.768% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 149.216% |
| GlycoMimetics, Inc. | -39.12 Million USD | 360.025% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 144.728% |
| ADMA Biologics, Inc. | 5.12 Million USD | -1886.855% |
| Clene Inc. | -43.24 Million USD | 335.256% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 133.958% |
| Aptose Biosciences Inc. | -52.26 Million USD | 294.626% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 194.416% |
| Soligenix, Inc. | -7.85 Million USD | 1395.415% |
| Century Therapeutics, Inc. | -121.2 Million USD | 183.928% |
| Kura Oncology, Inc. | -164.95 Million USD | 161.67% |
| Surrozen, Inc. | -41.13 Million USD | 347.324% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 227.003% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 10721.579% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 2460.803% |
| Autolus Therapeutics plc | -156.77 Million USD | 164.889% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 220.164% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 610.319% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 190.397% |
| GRI Bio, Inc. | -10.89 Million USD | 1033.447% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 2352.733% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 243.229% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 198.01% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 366.767% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 763.542% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 1336.596% |
| Jaguar Health, Inc. | -33.13 Million USD | 407.045% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 746.163% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 278.955% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 541.179% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 138.244% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 152.453% |
| Verastem, Inc. | -83.16 Million USD | 222.318% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 164.291% |
| Histogen Inc. | -10.5 Million USD | 1068.552% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 812.389% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 249.98% |
| Surrozen, Inc. | -41.13 Million USD | 347.324% |
| Organovo Holdings, Inc. | -14.8 Million USD | 787.066% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -3171929.935% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 1320.04% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 161.257% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 306.517% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 775.701% |
| Kronos Bio, Inc. | -121.83 Million USD | 183.499% |
| Turnstone Biologics Corp. | -56.23 Million USD | 280.899% |
| Synaptogenix, Inc. | -8.3 Million USD | 1324.519% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 763.192% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 31790.654% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 261.351% |
| Exelixis, Inc. | 196.6 Million USD | 48.257% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 171.938% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 120.542% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 256.539% |
| ESSA Pharma Inc. | -26.45 Million USD | 484.524% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 2643.209% |
| Avid Bioservices, Inc. | -11.48 Million USD | 986.047% |
| Insmed Incorporated | -654.73 Million USD | 115.537% |
| MediWound Ltd. | -4.89 Million USD | 2179.031% |
| OmniAb, Inc. | -49.73 Million USD | 304.555% |
| Alector, Inc. | -142.89 Million USD | 171.192% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 219.071% |
| Zai Lab Limited | -366.57 Million USD | 127.751% |
| AlloVir, Inc. | -190.14 Million USD | 153.499% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 135.001% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 192.691% |
| Aura Biosciences, Inc. | -83.69 Million USD | 221.543% |
| Immunic, Inc. | -99.11 Million USD | 202.638% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 177.259% |
| Veracyte, Inc. | -49.4 Million USD | 305.888% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 1540.091% |
| FibroGen, Inc. | -261.4 Million USD | 138.915% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 1013.087% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -17.181% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 1552.967% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 643.504% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 500.153% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -155.019% |
| Fortrea Holdings Inc. | 167.3 Million USD | 39.195% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 175.757% |
| XBiotech Inc. | -35.76 Million USD | 384.424% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 256.539% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 166.848% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -19130.057% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 255.903% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 197.388% |
| Agenus Inc. | -145.92 Million USD | 169.712% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 496.257% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 348.922% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 119.697% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 281.587% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 187.443% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 558.859% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 183.312% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 1941.03% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 500.626% |
| Lantern Pharma Inc. | -15.78 Million USD | 744.385% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ainos, Inc. | -8.77 Million USD | 1259.533% |
| Pluri Inc. | -20.22 Million USD | 602.977% |
| Prothena Corporation plc | -190.1 Million USD | 153.51% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 179.351% |
| Rallybio Corporation | -72.37 Million USD | 240.559% |
| Kodiak Sciences Inc. | -259.02 Million USD | 139.273% |
| Cue Biopharma, Inc. | -46.05 Million USD | 320.896% |
| MeiraGTx Holdings plc | -57.05 Million USD | 278.306% |
| Annexon, Inc. | -141.57 Million USD | 171.854% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 258.463% |
| Moderna, Inc. | -3.28 Billion USD | 103.099% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 625.124% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 517.513% |
| Blueprint Medicines Corporation | -474.61 Million USD | 121.434% |
| Immix Biopharma, Inc. | -16.13 Million USD | 730.449% |
| CalciMedica, Inc. | -34.18 Million USD | 397.543% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 174.205% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 160.39% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 273.035% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 140.305% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 408.582% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 200.506% |
| Nutriband Inc. | -5.12 Million USD | 2086.166% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 335.087% |
| Vor Biopharma Inc. | -114.37 Million USD | 188.945% |
| Roivant Sciences Ltd. | -996.51 Million USD | 110.208% |
| Alkermes plc | 495.04 Million USD | 79.451% |
| ProKidney Corp. | -147.66 Million USD | 168.889% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 257.631% |
| Arcellx, Inc. | -64.14 Million USD | 258.589% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 117.99% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 191.024% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 50459.901% |
| Atai Life Sciences N.V. | -36.31 Million USD | 380.155% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 227.931% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 225.105% |
| MediciNova, Inc. | -9.87 Million USD | 1129.629% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 180.774% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 6747.95% |
| GeoVax Labs, Inc. | -26.66 Million USD | 481.446% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 145.214% |
| Biomea Fusion, Inc. | -124.62 Million USD | 181.63% |
| RenovoRx, Inc. | -11.39 Million USD | 993.126% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 153.445% |
| Geron Corporation | -174.78 Million USD | 158.202% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 438.808% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 194.967% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 143.571% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 545.097% |
| Royalty Pharma plc | 1.88 Billion USD | 94.61% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 148.946% |
| Imunon, Inc. | -19.87 Million USD | 611.75% |
| BioAtla, Inc. | -122.24 Million USD | 183.218% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 133.876% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 345.439% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 161.252% |
| Structure Therapeutics Inc. | -102.45 Million USD | 199.286% |
| 89bio, Inc. | -134.46 Million USD | 175.654% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 202.492% |
| aTyr Pharma, Inc. | -52.17 Million USD | 294.961% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 221.371% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 143.368% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 1364.899% |
| Akari Therapeutics, Plc | -16.8 Million USD | 705.446% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -53807.666% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 77.491% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 162.232% |
| Liquidia Corporation | -70.05 Million USD | 245.218% |
| Entera Bio Ltd. | -8.8 Million USD | 1255.463% |
| GH Research PLC | -41.15 Million USD | 347.192% |
| Vericel Corporation | 2.86 Million USD | -3451.92% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 243.306% |
| Xencor, Inc. | -125.87 Million USD | 180.817% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 7231.005% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 763.542% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 604.658% |
| Vaxcyte, Inc. | -464.88 Million USD | 121.882% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 148.323% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 1029.693% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 1692.314% |
| Portage Biotech Inc. | -18.19 Million USD | 658.97% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 6747.95% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 197.268% |
| OncoCyte Corporation | -23.12 Million USD | 539.939% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 1000.21% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 987.915% |
| Purple Biotech Ltd. | -22.22 Million USD | 557.714% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 453.513% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 451.231% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 160.385% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 1687.005% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 444.791% |
| United Therapeutics Corporation | 1.38 Billion USD | 92.665% |
| HilleVax, Inc. | -132.46 Million USD | 176.795% |
| Silo Pharma, Inc. | -3.62 Million USD | 2905.323% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 1763.145% |
| Pharming Group N.V. | 9.87 Million USD | -929.938% |
| Tharimmune, Inc. | -9.3 Million USD | 1193.534% |
| Genprex, Inc. | -31.06 Million USD | 427.512% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 221.125% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 154.247% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 229.6% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 13415.052% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -67311.732% |
| OKYO Pharma Limited | -15.74 Thousand USD | 646155.124% |
| Savara Inc. | -59.13 Million USD | 272.031% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 604.623% |
| Curis, Inc. | -45.13 Million USD | 325.364% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 769.647% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 480.515% |
| BeiGene, Ltd. | -1.12 Billion USD | 109.046% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 212.605% |
| Erasca, Inc. | -121.31 Million USD | 183.857% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 2361.225% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 2361.225% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 338.745% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 1901.115% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 269.964% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 173.167% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 149.416% |
| Adicet Bio, Inc. | -136.53 Million USD | 174.506% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 210.478% |
| Aditxt, Inc. | -25.45 Million USD | 499.588% |
| Adagene Inc. | -14.95 Million USD | 780.412% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1491.596% |
| Quantum-Si incorporated | -91.8 Million USD | 210.809% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 19.555% |
| Compugen Ltd. | -12.51 Million USD | 912.776% |
| Generation Bio Co. | -133.3 Million USD | 176.314% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 222.518% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 218.256% |
| Invivyd, Inc. | -196.61 Million USD | 151.739% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 127.189% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 1196.811% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -274.63% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 1089.081% |
| 2seventy bio, Inc. | -206.41 Million USD | 149.282% |
| Instil Bio, Inc. | -146.12 Million USD | 169.618% |
| Capricor Therapeutics, Inc. | -23 Million USD | 542.119% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 2482.174% |
| GeoVax Labs, Inc. | -26.66 Million USD | 481.446% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 376.964% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -1971.725% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 164.22% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 114.866% |
| Evaxion Biotech A/S | -21.4 Million USD | 575.293% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 253.169% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 146.735% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 227.811% |
| Cingulate Inc. | -22.95 Million USD | 543.216% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 1463.45% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 372.851% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 274.274% |
| Clearmind Medicine Inc. | -8.71 Million USD | 1267.845% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 236.837% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 4266.725% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 200.893% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 126.772% |
| ImmunityBio, Inc. | -436.18 Million USD | 123.322% |
| Korro Bio, Inc. | -80.9 Million USD | 225.738% |
| Kineta, Inc. | -15.71 Million USD | 747.365% |
| BioVie Inc. | -31.95 Million USD | 418.392% |
| Codexis, Inc. | -49.28 Million USD | 306.414% |
| Celularity Inc. | -183.94 Million USD | 155.303% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 751.553% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 145.924% |
| Virax Biolabs Group Limited | -6.6 Million USD | 1639.186% |
| Cibus, Inc. | -314.58 Million USD | 132.337% |
| IN8bio, Inc. | -28.5 Million USD | 456.887% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 190.344% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 463.896% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 144.227% |
| Eyenovia, Inc. | -24.1 Million USD | 521.998% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -127.15% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 31497.222% |
| Elevation Oncology, Inc. | -41.46 Million USD | 345.32% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 237.834% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 325.99% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 182.386% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 429.405% |
| Moolec Science SA | -52.07 Million USD | 295.345% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 297.122% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 351.694% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 185.061% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 309.863% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 1190.993% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 590.469% |
| Humacyte, Inc. | -96.45 Million USD | 205.462% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 228.972% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -2410.538% |
| Genelux Corporation | -24.16 Million USD | 520.968% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 400.967% |
| Notable Labs, Ltd. | -14.4 Million USD | 806.438% |
| Immunovant, Inc. | -269.97 Million USD | 137.68% |
| Quantum-Si incorporated | -91.8 Million USD | 210.809% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 626.865% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 199.721% |
| Acasti Pharma Inc. | -11.3 Million USD | 1000.159% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 557.133% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 374.715% |
| PepGen Inc. | -83.58 Million USD | 221.709% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 544.281% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 2231.866% |
| Immuneering Corporation | -58.06 Million USD | 275.208% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -3171929.935% |
| Belite Bio, Inc | -31.52 Million USD | 422.646% |
| XOMA Corporation | -39.36 Million USD | 358.44% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 250.825% |
| Bionomics Limited | -9.83 Million USD | 1134.127% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 393.958% |
| uniQure N.V. | -253.1 Million USD | 140.192% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1491.596% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 178.551% |
| Forte Biosciences, Inc. | -32.47 Million USD | 413.228% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 1363.615% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 460.491% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 31497.222% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 1013.087% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 739.752% |
| Altimmune, Inc. | -87.93 Million USD | 215.684% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 183.216% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 393.958% |
| Peak Bio, Inc. | -1356.23 USD | 7500818.905% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 309.323% |
| Benitec Biopharma Inc. | -22.49 Million USD | 552.321% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 141.983% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 456.399% |
| Zura Bio Limited | -60.56 Million USD | 267.969% |
| PolyPid Ltd. | -20.26 Million USD | 602.033% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 456.399% |
| argenx SE | -216.02 Million USD | 147.091% |
| Immunome, Inc. | -28.27 Million USD | 459.828% |
| Verona Pharma plc | -52.46 Million USD | 293.885% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 207.339% |
| Shattuck Labs, Inc. | -87.61 Million USD | 216.107% |
| CervoMed Inc. | -2.17 Million USD | 4783.835% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 901.442% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 311.166% |
| Moolec Science SA | -52.07 Million USD | 295.345% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 693.507% |
| Design Therapeutics, Inc. | -66.32 Million USD | 253.377% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 225.609% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 369.475% |
| Achilles Therapeutics plc | -70.44 Million USD | 244.412% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 4266.725% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 283.517% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 301.24% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 255.839% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 288.001% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 324.187% |
| Beam Therapeutics Inc. | -156.47 Million USD | 165.012% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 174.531% |
| AEON Biopharma, Inc. | -48.36 Million USD | 310.349% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 255.629% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 224.16% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 923.699% |
| NeurAxis, Inc. | -6.66 Million USD | 1626.402% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 123.8% |
| Lumos Pharma, Inc. | -36.57 Million USD | 378.171% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -1645.114% |
| Palisade Bio, Inc. | -12.28 Million USD | 928.328% |
| Nutriband Inc. | -5.12 Million USD | 2086.166% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 196.701% |
| Neurogene Inc. | -52.28 Million USD | 294.559% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 1311.613% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 209.363% |
| Athira Pharma, Inc. | -116.7 Million USD | 187.167% |
| HCW Biologics Inc. | -23.57 Million USD | 531.484% |
| XOMA Corporation | -39.36 Million USD | 358.44% |
| Nektar Therapeutics | -243.1 Million USD | 141.845% |
| Arvinas, Inc. | -394.8 Million USD | 125.767% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -53807.666% |
| Merus N.V. | -149.2 Million USD | 168.178% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 208.811% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 425.422% |
| Rezolute, Inc. | -68.42 Million USD | 248.674% |
| Clene Inc. | -43.24 Million USD | 335.256% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 759.614% |
| BeyondSpring Inc. | -21.54 Million USD | 572.27% |
| Synlogic, Inc. | -55.16 Million USD | 284.418% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 941.902% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 1055.901% |
| Peak Bio, Inc. | -1356.23 USD | 7500818.905% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 413.344% |
| Krystal Biotech, Inc. | 17.9 Million USD | -468.18% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 185.901% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 129.802% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 2308.369% |
| MannKind Corporation | 15.12 Million USD | -572.397% |
| Ikena Oncology, Inc. | -74.39 Million USD | 236.735% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 907.806% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -400.453% |
| Gossamer Bio, Inc. | -172.15 Million USD | 159.091% |
| CohBar, Inc. | -12.06 Million USD | 943.105% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 498.789% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 438.808% |
| Legend Biotech Corporation | -477.87 Million USD | 121.287% |
| Mural Oncology plc | -192.72 Million USD | 152.785% |
| Disc Medicine, Inc. | -91.02 Million USD | 211.757% |
| Champions Oncology, Inc. | -5.05 Million USD | 2112.802% |
| REGENXBIO Inc. | -239.46 Million USD | 142.481% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 1049.106% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 282.45% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 362.398% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 190.179% |
| Vaxart, Inc. | -74.72 Million USD | 236.139% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 388.929% |
| Cellectis S.A. | -98.09 Million USD | 203.703% |
| Longeveron Inc. | -20.06 Million USD | 607.114% |
| Repare Therapeutics Inc. | -114.27 Million USD | 189.021% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 123.162% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 235.977% |
| Revolution Medicines, Inc. | -430.58 Million USD | 123.625% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 1717.539% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 430.4% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 236.382% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -1974.791% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 1027.743% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 97.791% |
| Denali Therapeutics Inc. | -179.97 Million USD | 156.523% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 106947.114% |
| Veru Inc. | -89.97 Million USD | 213.061% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 478.477% |
| Cingulate Inc. | -22.95 Million USD | 543.216% |
| Passage Bio, Inc. | -98.34 Million USD | 203.443% |
| Context Therapeutics Inc. | -25.06 Million USD | 505.924% |
| Exicure, Inc. | -15.53 Million USD | 754.656% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 149.367% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 375.116% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 1806.086% |
| Nuvalent, Inc. | -149.49 Million USD | 168.048% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 1350.883% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 218.433% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 437.09% |
| OmniAb, Inc. | -49.73 Million USD | 304.555% |
| Anew Medical, Inc. | -1.3 Million USD | 7920.101% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 922.768% |
| Lipocine Inc. | -16.32 Million USD | 723.225% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 252.583% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 236.908% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 366.767% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 360.745% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 558.581% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 118.663% |
| Ocugen, Inc. | -64.82 Million USD | 256.921% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 209.892% |
| Q32 Bio Inc. | -86.5 Million USD | 217.601% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 700.975% |
| Alumis Inc. Common Stock | -156.89 Million USD | 164.84% |
| Equillium, Inc. | -12.13 Million USD | 938.087% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 273.976% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 1387.138% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 639.352% |
| Dominari Holdings Inc. | -22.44 Million USD | 553.329% |
| Edesa Biotech, Inc. | -8.19 Million USD | 1342.066% |
| vTv Therapeutics Inc. | -25.41 Million USD | 500.311% |
| Bio-Techne Corporation | 326.66 Million USD | 68.859% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 126.432% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 52.989% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 177.59% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 371.772% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 167.324% |
| Nkarta, Inc. | -120.48 Million USD | 184.434% |
| BioCardia, Inc. | -11.56 Million USD | 979.991% |
| Iterum Therapeutics plc | -34.58 Million USD | 394.179% |